Researchers have published the largest map to date of gene activity in the human prefrontal cortex, analyzing more than 6.3 million cells from nearly 1,500 deceased donors. Published on September 23 across multiple journals including Nature, the landmark project links aging, genetic risk, and brain disorders like Alzheimer’s.
PsychAD Consortium Maps Millions of Brain Cells
Scientists have assembled the largest map to date of human brain gene activity, examining tissue samples from 1,494 donors ranging in age from infancy to 108 years old according to Reuters reporting. The monumental undertaking focuses on the prefrontal cortex, the front region of the brain’s outer layer that directs working memory, planning, decision-making, and emotional regulation.
The findings, unveiled on September 23, span a collection of studies published in Nature and other journals. The research was conducted by the PsychAD Consortium, an initiative funded by the National Institute on Aging under the U.S. National Institutes of Health. Tissue specimens were sourced from multiple institutional repositories, including 1,042 samples from the Mount Sinai NIH Neurobiobank, 300 from the NIMH-IRP Human Brain Collection Core, and 152 samples derived from prospective cohort studies at the Rush Alzheimer’s Disease Center as detailed in the primary data filings.
“The scale of this project and the amount of work required to assemble it are genuinely impressive.”
Zhichao Miao, computational biologist at the Guangzhou National Laboratory
Researchers utilized single-cell RNA sequencing to capture active RNA transcripts within individual nuclei. This high-resolution approach recorded gene activity across more than 6.3 million cells, mapping neurons, immune cells, vascular cells, and support cells within the prefrontal cortex.
Lifespan Development and Brain Aging Milestones
By comparing healthy brain samples across ages, the consortium established a baseline reference distinguishing normal aging from pathological decline. Investigators identified three distinct developmental periods within the cortex: an early rapid remodeling phase, a stable mid-life plateau beginning around age 24, and a secondary remodeling phase that starts around age 65 as outlined by the research team.
“This provides a reference for distinguishing typical aging from disease-associated changes.”
Dr. Panos Roussos, director of the Center for Disease Neurogenomics at the Icahn School of Medicine at Mount Sinai
Dr. Roussos emphasized that identifying age 24 as a transition point toward stability does not signify that brain development abruptly concludes or that neurological decline begins immediately according to statements provided to Reuters. Instead, core cellular populations stabilize while other biological processes continue shifting throughout life.
Analysis of daily circadian rhythms revealed that clock genes display synchronized activity patterns in the neurons of younger and middle-aged adults. In contrast, older adults exhibit weaker and less coordinated circadian organization, pointing to potential links between disrupted biological rhythms and brain aging notes from the study indicate.
Shared Molecular Pathways in Neurodegenerative Disorders
The donor cohort included neurotypical controls alongside individuals diagnosed with one of eight distinct conditions: Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, vascular dementia, tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder according to institutional metadata. Cross-disorder comparisons demonstrated that Alzheimer’s disease, Lewy body disease, vascular dementia, and Parkinson’s share strong similarities in gene activity related to neuronal communication, nerve-cell development, and blood-vessel biology pursuant to the consortium’s findings.
Additionally, researchers uncovered shared pathways in microglia—the brain’s resident immune cells—specifically connecting Alzheimer’s and Parkinson’s diseases. For individuals who maintained cognitive function despite experiencing substantial Alzheimer’s pathology, gene activity displayed differences in energy-related processes in brain cells, offering potential clues toward natural protective mechanisms as reported by Reuters.
“A useful treatment needs to influence the right biological process in the right cells. This map helps narrow that search. It can identify vulnerable cell populations, reveal processes associated with preserved brain function and help researchers decide which potential treatment targets to test.”
Dr. Panos Roussos, director of the Center for Disease Neurogenomics at the Icahn School of Medicine at Mount Sinai
By mapping inherited genetic risks to more than 14,000 specific genes and their corresponding cell types, the PsychAD Consortium aims to accelerate targeted therapeutic development. While the prefrontal cortex offers an essential lens into psychiatric and neurodegenerative conditions, researchers noted that examining additional brain regions will be necessary to construct a complete molecular picture of human neurological disease concluded study authors.
Worth a look